...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
AGORACOM NEWS FLASH

Dear Agoracom Family,

I want to thank all of you for your patience with us over the past 48 hours and apologize for what was admittedly a botched launch of our new site.

As you can see, we have reverted back to the previous version of the site while we address multiple forum functionality flaws that inexplicably made their way into the launch.

To this end:

1.We have identified 8 fundamental but easily fixable flaws that will be corrected in the coming week, so that you can continue to use the forums exactly as you've been accustomed to.

2.Additionally we will also be implementing a couple of design improvements to "tighten up" the look and feel of the forums.

Sincerely,

George et al

Message: Quote from a January 19, 2021 review

,,,aaaccchh,,do readers here really think that experienced biotech investing firms and or fund managers with vast resources havent done DD and dont know this???,,,, really??,,I beg to differ and would say they are so far ahead of retail investors like ourselves that such papers add little value this late to the buffet as dutchfellow would say...all imo.  208 has been in the public research domain for years,,,,,and as noted you could buy it for research off the market which I assume was produced by the RVX manufacturing sub or subs!,,,,

Share
New Message
Please login to post a reply